Argenx stock ahead of the Xetra open with immunology focus
Published on 10/20/2026 at 09:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness model and last session
- Argenx develops immunology therapies for patients with immune-mediated diseases.
- The last quoted Euronext Brussels session was October 19, 2026.
- Argenx stock last traded at EUR 729.80 at 5:39 p.m. CEST on Euronext Brussels on October 19, 2026.
Argenx develops immunology therapies for patients with immune-mediated diseases, with its portfolio including VYVGART and VYVGART Hytrulo, according to the company's investor information. The stock was last at EUR 729.80 on Euronext Brussels on October 19, 2026 at 5:39 p.m. CEST.
Argenx and its business
The company describes itself as an immunology business focused on research, clinical development and approved therapies. Its investor site lists financial reports, events and presentations, shareholder meetings and securities documents among its investor resources.
Trading context
The October 19, 2026 Euronext Brussels session provides the latest dated euro reference for the stock. The first price of the day is shown from the start of trading by the continuously updated real-time quote of Argenx stock.
Market context: Market report Euro Stoxx 50.
